CGTX
Cognition Therapeutics Accelerates Progress with Breakthroughs in Dementia with Lewy Bodies Treatment
Cognition Therapeutics has made significant strides in the treatment of dementia with Lewy bodies (DLB) through its commitment to advancing zervimesine, a unique small molecule designed to slow disease progression. The company recently announced alignment with the FDA on a planned registrational trial for zervimesine in individuals living with DLB,